The published record for these two compounds is small enough to list in full.
Published, peer-reviewed
Study What it tested Subjects Result Status
Raun et al., 1998, Eur J Endocrinol Ipamorelin discovery Rat pituitary cells, rats, pigs GH release matching GHRP-6, no ACTH or cortisol rise at 200× effective dose Published, animal
Gobburu et al., 1999, Pharm Res Ipamorelin pharmacokinetics 40 healthy men, single IV infusion, five doses Single GH pulse peaking at 0.67 h; half-life about 2 h Published
Lall et al., 2001, BBRC Ipamorelin vs GH on fat GH-deficient and normal mice, 2–9 weeks Ipamorelin increased body fat, fat-pad weight, leptin, food intake; GH decreased fat Published, animal
Beck et al., 2014, Int J Colorectal Dis Ipamorelin for postoperative ileus 117 adults after bowel resection, IV 0.03 mg/kg twice daily up to 7 days Time to first tolerated meal 25.3 vs 32.6 h, p = 0.15. No significant difference on any endpoint Published, negative
NCT01280344 Second ipamorelin ileus trial 320 adults, Phase 2, sponsor Helsinn Completed May 2014. No results posted, never published Unpublished
Teichman et al., 2006, JCEM CJC-1295 DAC ascending dose Healthy adults 21–61, two trials of 28 and 49 days GH 2–10× for 6+ days; IGF-1 1.5–3× for 9–11 days; half-life 5.8–8.1 days Published
Ionescu & Frohman, 2006, JCEM CJC-1295 DAC and GH pulsatility Healthy men 20–40, single dose of 60 or 90 mcg/kg Pulses preserved; trough GH up 7.5×; mean GH +46%; IGF-1 +45% Published
NCT00267527 CJC-1295 DAC in HIV-associated visceral obesity Phase 2, ConjuChem; 192 enrolled per contemporary reports Terminated July 17, 2006 after a participant’s death. Data never published Unpublished
Ben-Shlomo et al., 2020, J Clin Invest Long-acting GHRH analogue and pituitary DNA damage Mouse pituitary cells; mice injected 8 weeks DNA damage in GH-producing cells in culture and in living mice, with pituitary enlargement Published, mechanistic
Unpublished, marketing, or absent
Claim Where it comes from Status
The combination releases more GH than either alone Extrapolated from 1990s studies of GHRH plus older GHRPs Never measured for this pair, in anyone
Muscle gain, fat loss, faster recovery, better sleep, better skin Clinic pages, forum threads, before-and-after posts No human study of either compound has measured any of them
The no-DAC version gives a cleaner, more natural pulse Community pharmacology The no-DAC form has never been given to a person under observation
Safe, based on years of prescribing Industry presentation to the FDA committee in December 2024 citing 449,184 dispensed CJC-1295 prescriptions Dispensing counts are not safety data. The committee did not accept the argument
Read the two tables together
Every human study is a pharmacology study: it measures hormone levels, not outcomes. Every outcome anyone is paying for lives in the second table. The 2026 Frontiers review reached the same conclusion, describing the stacking practice as driven largely by anecdotal rationale.
Conclusion
The stack’s scientific case is an extrapolation from hormone curves to body composition, and nobody has ever checked whether the extrapolation holds.